AXIM - AXIM Biotechnologies begins trials on Immunopass rapid diagnostic test

AXIM Biotechnologies (AXIM) announces the start of clinical trials for ImmunoPass, the company’s rapid point-of-care test that semi-quantitatively measures levels of neutralizing antibodies to COVID-19.Measuring neutralizing antibodies in people after vaccination may give a better look at how COVID-19 vaccine responses hold up over time.AXIM’s ImmunoPass has shown a significantly better statistical correlation with SARS-CoV-2 neutralization assays than the currently available antibody tests, the company said.The test is based on blocking the interaction between human cell receptors and the viral spike protein that mimics the virus neutralization process in the body.

For further details see:

AXIM Biotechnologies begins trials on Immunopass rapid diagnostic test